Virion Therapeutics, LLC, a clinical-stage biotechnology company, developing novel T cell-based immunotherapies that utilize ...
Please provide your email address to receive an email when new articles are posted on . Among patients with low baseline HBsAg, 39% achieved HBsAg loss with tobevibart/elebsiran, which rose to 46% ...
Tune-401 achieved dose-dependent HBsAg reductions (mean 54% at 0.65 mg/kg) with durable, months-long pharmacodynamics after single dosing on stable nucleos(t)ide analog background. Multiple recipients ...
Combination tobevibart 300 mg + elebsiran 200 mg q4w achieved HDV RNA TND in 77% at week 72 and 88% at week 96, outperforming tobevibart monotherapy. Profound HBsAg lowering occurred with dual therapy ...
Please provide your email address to receive an email when new articles are posted on . Older age, male sex and increased hepatitis B surface antigen correlated with a higher risk for hepatic flare ...
Panel A shows the structure of HDV, which shares the hepatitis B surface antigen (HBsAg) envelope with hepatitis B virus. The virion contains a single-stranded, circular RNA genome of approximately ...
Patients with chronic hepatitis B virus (HBV) infection in the immune-tolerant phase may still experience hepatic inflammation and disease progression, and could benefit from early antiviral treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results